## Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Analysis Report - December 20, 2024

**1. Company Overview:**

Sun Pharmaceutical Industries Limited (SUNPHARMA) is a leading pharmaceutical company operating in the Pharmaceuticals industry.  Listed on the NSE since February 8, 1995, it holds a significant position within the Indian pharmaceutical sector and has a global presence.  The company is involved in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,810.00       |                                                                      |
| Percentage Change (PChange) | -0.73%          | Negative change indicating a slight downward trend in the day's trading. |
| Pre-Open Activity          | ₹1,823.30       |  Pre-open price higher than the closing price, suggesting potential buying interest.  |
| Week High                   | ₹1,960.35       | High reached on September 30, 2024.                               |
| Week Low                    | ₹1,208.55       | Low reached on December 21, 2023.  Significant volatility observed. |
| VWAP                        | ₹1,808.38       | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 38.74           | Sector Price-to-Earnings ratio.                                     |
| Symbol PE                   | 39.28           | SUNPHARMA's Price-to-Earnings ratio.                               |
| Delivery Percentage         | 62.79%          | High delivery percentage suggests a significant portion of trades were genuine investments. |
| Market Depth                | Low              |  The provided data shows a low market depth (total buy and sell quantities in pre-open are low). This suggests limited liquidity.  Further analysis of order book depth is needed for a complete assessment. |


**3. Financial Performance:**

The following table summarizes the financial performance of SUNPHARMA over the past five quarters.  Note that the data provided includes both audited and unaudited results.  Profitability is inconsistent, showing both profits and losses.

| Quarter      | From Date     | To Date       | Income (₹)    | Expenditure (₹) | Profit After Tax (₹) | Diluted EPS |
|--------------|---------------|---------------|---------------|-----------------|----------------------|-------------|
| Q2 FY25      | 01-Jul-2024   | 30-Sep-2024   | 521,401        | 431,837          | 86,329                | 3.6         |
| Q1 FY25      | 01-Apr-2024   | 30-Jun-2024   | 458,081        | 432,289          | 23,782                | 1           |
| Q4 FY24      | 01-Jan-2024   | 31-Mar-2024   | 575,802        | 435,624          | 86,760                | 3.6         |
| Q3 FY24      | 01-Oct-2023   | 31-Dec-2023   | 515,055        | 432,927          | 72,131                | 3           |
| Q2 FY24      | 01-Jul-2023   | 30-Sep-2023   | 520,275        | 429,623          | 88,863                | 3.7         |


**Key Financial Ratios:**  Further analysis requires additional financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others.  The provided data is insufficient for a comprehensive ratio analysis.


**4. Corporate Actions and Announcements:**

SUNPHARMA has a history of consistent dividend payouts. Recent dividends include ₹5 per share (ex-date 12-Jul-2024), ₹8.50 per share (ex-date 09-Feb-2024), and others.  Several recent announcements relate to shareholder meetings and newspaper publications.  No significant negative announcements impacting stock performance are evident from the provided data.


**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 31-Dec-2023  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 31-Mar-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 30-Jun-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|
| 30-Sep-2024  | 54.48%                     | 45.52% | 0.00%                         | 100.00%|

Promoter holding remains stable over the past year.


**6. Volatility and Risk Assessment:**

The week's high and low prices show significant volatility. The CM Annual Volatility of 22.35% further confirms this.  The risk-reward profile is currently high risk due to the volatility and inconsistent profitability.


**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Strong promoter holding.
* Established player in the pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility.
* Inconsistent profitability in recent quarters.
* Limited liquidity based on the provided market depth data.
* Requires further financial analysis for a complete risk assessment.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price decline and high volatility make a short-term buy risky.  Holding is recommended until more clarity emerges on the financial performance and market sentiment.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on the company's ability to improve profitability and stabilize its performance.  Further monitoring of financial results is crucial.

* **Long-term (1 year and beyond): Hold/Consider Buy (with caution).**  SUNPHARMA's established position in the pharmaceutical sector and consistent dividend history offer long-term potential. However, the recent financial inconsistencies warrant caution.  A thorough fundamental analysis, including a detailed review of the company's financials and future growth prospects, is necessary before considering a long-term buy.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 6/10 (Inconsistent profitability in recent quarters)
* Market Performance: 7/10 (Stable promoter holding, but high volatility)
* Volatility and Risk: 4/10 (High volatility, limited liquidity)
* Corporate Actions & Governance: 8/10 (Consistent dividend payouts, no major negative announcements)
* Shareholding Patterns: 9/10 (Stable promoter holding)

**Analysis Score (out of 10): 7/10**

* Completeness and utilization of data: 8/10 (Most data used, but some ratios couldn't be calculated)
* Accuracy and clarity of analysis: 7/10 (Analysis is clear, but some limitations due to data constraints)
* Professional formatting: 8/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

Based on the analysis of the provided data, a cautious approach is recommended. While SUNPHARMA has strengths such as consistent dividend payouts and a strong promoter holding, the recent financial inconsistencies and high volatility present significant risks.  A "Hold" recommendation is given for the short and medium term, with a "Hold/Consider Buy (with caution)" recommendation for the long term, contingent upon further due diligence and a more comprehensive financial analysis.  Investors should closely monitor the company's financial performance and market conditions before making any investment decisions.
